← Eichor
Study identifier: NCT03855722 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)

Condition: Transplant Dysfunction  ·  Sponsor: Helsinki University Central Hospital

PhaseNA
Planned participants496
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.

This description comes directly from the study's public registry record.

Talk to the study team

Ville Sallinen, MD, PhD  ·  +358-9-4711  ·  ville.sallinen@helsinki.fi

Aki Uutela, MD  ·  +358-9-4711  ·  aki.uutela@hus.fi

Always discuss trial participation with your own doctor first.

Locations (1)

Helsinki University HospitalHelsinki, FinlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03855722